Charles River Laboratories International financials
$295.96+0.47%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 27 | Q1 '26 Mar 28 | Q4 '25 Dec 27 | Q3 '25 Sep 27 | Q2 '25 Jun 28 | Q1 '25 Mar 29 | Q4 '24 Dec 28 | Q3 '24 Sep 28 | Q2 '24 Jun 29 | Q1 '24 Mar 30 | Q4 '23 Dec 30 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $995.8M | $994.2M | $1.00B | $1.03B | $984.2M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B |
| Gross profit | $363.4M | $294.7M | $309.7M | $338.8M | $357.1M | $317.7M | $284.2M | $349.0M | $353.7M | $344.8M | $364.1M | $361.8M |
| Gross margin | 36.2% | 29.6% | 31.1% | 33.7% | 34.6% | 32.3% | 28.4% | 34.6% | 34.5% | 34.1% | 35.9% | 35.2% |
| Operating income | $119.9M | $119.9M | -$283.4M | $133.8M | $100.1M | $74.7M | -$167.7M | $117.4M | $151.7M | $126.0M | $132.9M | $151.5M |
| Net income | -$1.5M | -$14.8M | -$276.6M | $54.4M | $52.3M | $25.5M | -$215.7M | $68.7M | $90.0M | $67.3M | $187.1M | $87.4M |
| Net margin | −0.1% | −1.5% | −27.8% | 5.4% | 5.1% | 2.6% | −21.5% | 6.8% | 8.8% | 6.7% | 18.5% | 8.5% |
| Diluted EPS | $-0.03 | $-0.30 | $-5.68 | $1.10 | $1.06 | $0.50 | $-4.21 | $1.33 | $1.74 | $1.30 | $3.65 | $1.69 |
| EBITDA | $187.2M | $187.0M | $170.8M | $219.0M | $219.6M | $195.0M | $149.4M | $205.6M | $237.7M | $211.3M | $132.9M | $230.4M |
| Operating cash flow | $179.7M | $41.1M | $147.5M | $213.8M | $204.6M | $171.7M | $159.4M | $251.8M | $193.5M | $129.9M | $220.9M | $205.4M |
| Free cash flow | $148.6M | -$14.8M | -$71.6M | $119.2M | $169.3M | $112.4M | -$73.6M | $133.2M | $154.0M | $50.7M | $142.6M | $139.5M |
| Diluted shares | 48.0M | 49.0M | 48.7M | 49.4M | 49.3M | 50.9M | 51.2M | 51.6M | 51.8M | 51.8M | 51.3M | 51.6M |
Balance sheet
| Period end | Jun 27 | Mar 28 | Dec 27 | Sep 27 | Jun 28 | Mar 29 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $192.0M | $191.8M | $213.8M | $207.1M | $182.8M | $229.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $2.62B | $2.66B | $2.14B | $2.19B | $2.33B | $2.51B |
| Total assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B |
| Total liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B |
| Shareholders' equity | $2.85B | $2.95B | $3.17B | $3.41B | $3.36B | $3.20B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology